☰

Kate Feldinger - Publications

Affiliations: 
2014-2017 University of Oxford, Oxford, United Kingdom 
Tree Info Similar researchers PubMed Report error

5/5 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Valli A, Morotti M, Zois CE, Albers PK, Soga T, Feldinger K, Fischer R, Frejno M, McIntyre A, Bridges E, Haider S, Buffa FM, Baban D, Rodriguez M, Yanes O, et al. Adaptation to HIF1α deletion in hypoxic cancer cells by upregulation of GLUT14 and creatine metabolism. Molecular Cancer Research : McR. PMID 30885992 DOI: 10.1158/1541-7786.MCR-18-0315  0.496
2015 Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Medical Press). 7: 147-62. PMID 26089701 DOI: 10.2147/BCTT.S54414  0.636
2015 Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer Breast Cancer: Targets and Therapy. 7: 147-162. DOI: 10.2147/BCTT.S54414  0.636
2014 Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, et al. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 5: 6633-46. PMID 24952873  0.521
2012 Feldinger K, Kerry J, Gijsen M, Murphy G, Kong A. 86P The Role of Adam17 in Her2 Moderately Expressing Breast Cancer Annals of Oncology. 23: ii39. DOI: 10.1016/s0923-7534(19)65750-9  0.683
Hide low-probability matches.